Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

H. Lundbeck A/S Denmark

PROCEED is an adaptive Phase IIb trial with Lu AG09222, an investigational mAb intended to block signaling by pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that is believed to contribute to migraine.The PROCEED trial is designed to explore different doses and routes of administration of Lu AG09222 in patients with migraine for whom one to four previous preventive treatments had failed to provide a benefit.Following the recruitment of approximately 75% of the patients in a subcutaneously (SC) administration dose-finding part of PROCEED, a pre-specified interim analysis is triggering an expansion of the trial, by the initiation of an intravenously (IV) dose-finding part.View original content:https://www.prnewswire.co.uk/news-releases/following-a-planned-interim-analysis-in-the-proceed-trial-lundbeck-expands-the-dose-finding-to-intravenous-administration-of-lu-ag09222-in-migraine-prevention-302415642.html